Posts Tagged: commercialization in Canada

MaRS Innovation joins new financing round for AvidBiologics Inc.

TORONTO, Sept. 29, 2014 — AvidBiologics Inc., an oncology drug development company, today announced the closing of a financing round. The company is founded on antibody-drug conjugate (ADC) technologies co-developed with the National Research Council of Canada (NRC). Led by Lumira Capital, the financing round included MaRS Innovation (MI), MaRS Investment Accelerator Fund (IAF), Rosseau Asset Management, and the company's founding investors. This announcement was covered by Dow Jones: Private Equity and Venture Capital and by Canadian Private Equity. Today's financing builds on prior ... Read more

Tech Transfer Central features MaRS Innovation’s partnership with St. Michael’s Hospital

Tech Transfer Tactics, the monthly newsletter for Tech Transfer Central.com, has published a feature highlighting MaRS Innovation's Technology Transfer & Scouting (MITTS) services to St. Michael's Hospital. The interview explores the increase in disclosures and commercial activity achieved after MaRS Innovation began offering technology transfer services to the hospital, and was triggered by a July profile published on MaRS Innovation's website describing the collaborative working relationship between the two organizations. The interview includes conversations with Sahail Shariff, commercialization manager in the MITTS division, ... Read more

Xagenic’s Shana Kelley named to Globe and Mail’s Top 12 Canadian Innovators

Dr. Shana Kelley, co-founder of Xagenic Inc. and a professor of biochemistry at the University of Toronto, has been named to the Globe and Mail's Top 12 Canadian Innovators list. The contest solicited nominations from across Canada that were assessed by a panel of judges. According to the Globe, the contest "recognizes talented Canadians who not only have great ideas, but also turn them into reality." Here's an excerpt: Another innovator who is taking on the traditional way of doing things is Ms. Kelley, ... Read more

Accel-Rx, the national health sciences accelerator, launches as a Centre of Excellence for Commercialization and Research (CECR)

MaRS Innovation among founding partner CECRs; Accel-Rx will provide funds to new biotechnology start-ups emerging within MI's portfolio VANCOUVER, BC (Aug. 25, 2014) –With the awarding of $14.5M under the Canadian government’s Networks of Centres of Excellence (Centres of Excellence for Commercialization and Research (CECR)) Program, as announced earlier this morning by the Honourable Ed Holder, Minister of State for Science and Technology, Accel-Rx - Canada’s Health Sciences Accelerator is officially launched. Media coverage of this announcement: CBC's Inside Politics blog, IT Business ... Read more

MaRS Innovation and St. Michael’s Hospital revitalizing commercialization process

For principal investigators, a key component in taking their research ideas from the bench to the market is knowing what commercialization resources exist and when to use them. Through the MaRS Innovation's Technology Transfer & Scouting division (MITTS), manager Sahail Shariff is connecting with principal investigators (PIs) at St. Michael's Hospital in Toronto on the front-line to better understand and advance their research. Of the 180 PIs at the hospital, the majority are clinician scientists who spend a portion of their time caring for patients. In collaboration ... Read more

Dr. Rafi Hofstein in Biotechnology Focus: What will it take to regain Canada’s biotechnology leadership?

Biotechnology Focus, a compendium of the Canadian life sciences industry, has published a guest column by MaRS Innovation President & CEO, Dr. Raphael Hofstein. The article explores the role life sciences assets, financing and talented management--the three Ms--must play in revitalizing Canada's biotechnology sector: At the close of the 20th century, Canada was perceived as a key contributor to the success of the global biotech voyage. You know what happened next: the mechanisms to fund early ventures collapsed together with the collapse of the ... Read more

Accel-Rx Health Sciences Accelerator to Partner with BDC Venture Capital

MaRS Innovation co-partner in pan-Canadian effort to help create up to 20 leading start-up companies CEBIO International Conference, San Diego – June 25, 2014: BDC Venture Capital and the Accel-Rx Health Sciences Accelerator (Accel-Rx) announced today a collaboration to provide critical seed funding to new and emerging Canadian health sciences companies. This announcement was covered in TechVibes, PE HUB and BetaKit. Together, Accel-Rx, BDC Venture Capital, and CDRD Ventures Inc. (CVI) which will provide the initial management to launch Accel-Rx operations, would focus on ... Read more

Globe and Mail: Strong incubators are key to driving innovation

Jeff Cates' op-ed in the Globe and Mail's Small Business/Digital Innovation section on June 19, 2014 argues that incubators have a key role to play in fostering innovation, entrepreneurship and growing new industries in Ontario. Cates states this is particularly true when incubators when they provide programs and services to help young entrepreneurs succeed. The University of Toronto Early-Stage Technology program (UTEST), co-managed with MaRS Innovation, is one such program. UTEST is set to announce its third cohort within the next month. (more…) Read more

MI’s Fanny Sie to speak about 3D printing trends at two Toronto events

Fanny Sie, MaRS Innovation's head of imaging technologies and a manager in the Technology & Venture Development group, is speaking about bioprinting trends at two Toronto conferences this weekend. Sie is MI's commercialization lead on the Bioprinter, a licensenable technology from the University of Toronto and Sunnybrook Health Sciences Centre. Watch her interview on bioprinting with TVO's The Agenda, which aired in June 2013. First up is Digifest, an international festival celebrating digital creativity, which runs from May 8 to 10 at the Corus ... Read more

MaRS Innovation Statement on 2014 Ontario Budget

TORONTO, ON (May 2, 2014) – MaRS Innovation congratulates the government's deepened commitment to support the life sciences through research and innovation funding. In particular, the new $30 million Life Sciences Seed Venture Capital Fund will create a partnership between the Province of Ontario, the private sector and hospital foundations to finance Ontario-based life sciences companies. “As co-designers of this venture capital fund and one of its many champions, MaRS Innovation welcomes this news,” says Dr. Raphael (Rafi) Hofstein, president and CEO. ... Read more
Page 4 of 12« First...23456...10...Last »